180 related articles for article (PubMed ID: 35689436)
1. Proteome profiling of enzalutamide-resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration-resistant prostate cancer.
Csizmarik A; Keresztes D; Nagy N; Bracht T; Sitek B; Witzke K; Puhr M; Tornyi I; Lázár J; Takács L; Kramer G; Sevcenco S; Maj-Hes A; Jurányi Z; Hadaschik B; Nyirády P; Szarvas T
Int J Cancer; 2022 Oct; 151(8):1405-1419. PubMed ID: 35689436
[TBL] [Abstract][Full Text] [Related]
2. The prognostic value of serum MMP-7 levels in prostate cancer patients who received docetaxel, abiraterone, or enzalutamide therapy.
Szarvas T; Csizmarik A; Váradi M; Fazekas T; Hüttl A; Nyirády P; Hadaschik B; Grünwald V; Tschirdewahn S; Shariat SF; Sevcenco S; Maj-Hes A; Kramer G
Urol Oncol; 2021 May; 39(5):296.e11-296.e19. PubMed ID: 33046366
[TBL] [Abstract][Full Text] [Related]
3. Comparative proteome analysis identified CD44 as a possible serum marker for docetaxel resistance in castration-resistant prostate cancer.
Keresztes D; Csizmarik A; Nagy N; Módos O; Fazekas T; Bracht T; Sitek B; Witzke K; Puhr M; Sevcenco S; Kramer G; Shariat S; Küronya Z; Takács L; Tornyi I; Lázár J; Hadaschik B; Lászik A; Szűcs M; Nyirády P; Szarvas T
J Cell Mol Med; 2022 Feb; 26(4):1332-1337. PubMed ID: 34970839
[TBL] [Abstract][Full Text] [Related]
4. Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancer.
Csizmarik A; Nagy N; Keresztes D; Váradi M; Bracht T; Sitek B; Witzke K; Puhr M; Tornyi I; Lázár J; Takács L; Kramer G; Sevcenco S; Maj-Hes A; Hadaschik B; Nyirády P; Szarvas T
Prostate Cancer Prostatic Dis; 2023 Aug; ():. PubMed ID: 37634036
[TBL] [Abstract][Full Text] [Related]
5. Influence of abiraterone and enzalutamide on body composition in patients with metastatic castration resistant prostate cancer.
Fischer S; Clements S; McWilliam A; Green A; Descamps T; Oing C; Gillessen S
Cancer Treat Res Commun; 2020; 25():100256. PubMed ID: 33307509
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Metastatic Castration-resistant Prostate Cancer With Abiraterone and Enzalutamide Despite PSA Progression.
Becker DJ; Iyengar AD; Punekar SR; Ng J; Zaman A; Loeb S; Becker KD; Makarov D
Anticancer Res; 2019 May; 39(5):2467-2473. PubMed ID: 31092441
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive analysis of serum chromogranin A and neuron-specific enolase levels in localized and castration-resistant prostate cancer.
Szarvas T; Csizmarik A; Fazekas T; Hüttl A; Nyirády P; Hadaschik B; Grünwald V; Püllen L; Jurányi Z; Kocsis Z; Shariat SF; Sevcenco S; Maj-Hes A; Kramer G
BJU Int; 2021 Jan; 127(1):44-55. PubMed ID: 32314509
[TBL] [Abstract][Full Text] [Related]
8. Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer.
Moses M; Niu A; Lilly MB; Hahn AW; Nussenzveig R; Ledet E; Manogue C; Cotogno P; Lewis B; Layton J; Agarwal N; Sartor O; Barata PC
Cancer Treat Res Commun; 2020; 24():100193. PubMed ID: 32702615
[TBL] [Abstract][Full Text] [Related]
9. Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer Registry.
Bjartell A; Costa L; Kramer G; Zurawski B; Galli L; Werbrouck P; Ecke T; Parikh O; Bennamoun M; Garcia Freire C; Peer A; Ljungberg B; Cicin I; Smith E; Lukac M; Wapenaar R; Chowdhury S
Eur Urol Open Sci; 2022 Nov; 45():12-22. PubMed ID: 36353661
[TBL] [Abstract][Full Text] [Related]
10. Abiraterone Followed by Enzalutamide Versus Enzalutamide Followed by Abiraterone in Chemotherapy-naive Patients With Metastatic Castration-resistant Prostate Cancer.
Matsubara N; Yamada Y; Tabata KI; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H; Yano A; Kawakami S; Otsuka M; Fukasawa S
Clin Genitourin Cancer; 2018 Apr; 16(2):142-148. PubMed ID: 29042308
[TBL] [Abstract][Full Text] [Related]
11. Treatment with abiraterone and enzalutamide does not overcome poor outcome from metastatic castration-resistant prostate cancer in men with the germline homozygous HSD3B1 c.1245C genotype.
Lu C; Terbuch A; Dolling D; Yu J; Wang H; Chen Y; Fountain J; Bertan C; Sharp A; Carreira S; Isaacs WB; Antonarakis ES; De Bono JS; Luo J
Ann Oncol; 2020 Sep; 31(9):1178-1185. PubMed ID: 32387417
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of CXCR7 is a Novel Indicator for Enzalutamide Resistance in Castration-Resistant Prostate Cancer Patients.
Luo Y; Li Q; Yang X; Wei D; Feng B; Li M; Han Y; Zhao J; Lin Y; Li Q; Hou Z; Zhuang H; Jiang Y
Dis Markers; 2021; 2021():6649579. PubMed ID: 34413914
[TBL] [Abstract][Full Text] [Related]
13. ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
Emmett L; Subramaniam S; Joshua AM; Crumbaker M; Martin A; Zhang AY; Rana N; Langford A; Mitchell J; Yip S; Francis R; Hofman MS; Sandhu S; Azad A; Gedye C; McJannett M; Stockler MR; Davis ID;
BJU Int; 2021 Nov; 128(5):642-651. PubMed ID: 34028967
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Response to Enzalutamide Consecutively After Abiraterone Acetate/Prednisone Failure in Patients With Metastatic Castration-resistant Prostate Cancer.
Emamekhoo H; Barata PC; Edwin NC; Woo KM; Grivas P; Garcia JA
Clin Genitourin Cancer; 2018 Dec; 16(6):429-436. PubMed ID: 30236961
[TBL] [Abstract][Full Text] [Related]
15. [Establishment of enzalutamide-resistant human prostate cancer cell lines and screening of lncRNA and mRNA expression profiles].
Guan H; Ling ZX; Fang F; Mao LK; You ZH; Wang C; Chen SQ; Xu B; Chen M
Zhonghua Nan Ke Xue; 2018 Feb; 24(2):116-121. PubMed ID: 30156069
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Novel Hormone Agents in the Treatment of Metastatic Castration-resistant Prostate Cancer: A Real-world Retrospective Study.
Li JR; Wang SS; Chen CS; Yang CK; Lu K; Cheng CL; Hung SC; Chen SY; Hsu CY; Chiu KY
Anticancer Res; 2022 Oct; 42(10):4857-4866. PubMed ID: 36191989
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of bipolar androgen therapy in mCRPC after progression on abiraterone or enzalutamide: A systematic review.
Xiong X; Qiu S; Yi X; Xu H; Lei H; Liao D; Bai S; Peng G; Wei Q; Ai J; Yang L
Urol Oncol; 2022 Jan; 40(1):4.e19-4.e28. PubMed ID: 34548234
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic/Pharmacodynamic Relationship of Enzalutamide and Its Active Metabolite N-Desmethyl Enzalutamide in Metastatic Castration-Resistant Prostate Cancer Patients.
Joulia ML; Carton E; Jouinot A; Allard M; Huillard O; Khoudour N; Peyromaure M; Zerbib M; Schoemann AT; Vidal M; Goldwasser F; Alexandre J; Blanchet B
Clin Genitourin Cancer; 2020 Apr; 18(2):155-160. PubMed ID: 31630979
[TBL] [Abstract][Full Text] [Related]
19. Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer.
Guan X; Sun D; Lu E; Urrutia JA; Reiter RE; Rettig M; Evans CP; Lara P; Gleave M; Beer TM; Thomas GV; Huang J; Aggarwal RR; Quigley DA; Foye A; Chen WS; Youngren J; Weinstein AS; Stuart JM; Feng FY; Small EJ; Xia Z; Alumkal JJ
Clin Cancer Res; 2020 Sep; 26(17):4616-4624. PubMed ID: 32727885
[TBL] [Abstract][Full Text] [Related]
20. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.
van Soest RJ; van Royen ME; de Morrée ES; Moll JM; Teubel W; Wiemer EA; Mathijssen RH; de Wit R; van Weerden WM
Eur J Cancer; 2013 Dec; 49(18):3821-30. PubMed ID: 24200698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]